On Thursday, Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s shares declined -0.40% to $2.51.
Amarin Corporation plc (ADR) (AMRN) declared the presentation of findings from a new in vitro study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts.
The poster, titled “Eicosapentaenoic Acid (EPA) Reduces Glucose-induced Small Dense Low-Density Lipoprotein Oxidation In Vitro in a Manner Distinct from Other Triglyceride-Lowering Agents and Vitamin E,” presents data that shows exposure to eicosapentaenoic acid (EPA), an omega-3 fatty acid, inhibited glucose-induced oxidation of small dense LDL. This study examined the effects of EPA and other triglyceride-lowering agents on human sdLDL oxidation following exposure in vitro to hyperglycemic conditions. Exposure to hyperglycemic conditions resulted in a 55% enhance in human sdLDL oxidation as contrast to non-glucose-treated controls as measured by a marker of oxidation (malondialdehyde (MDA)). EPA inhibited this glucose-induced sdLDL oxidation in a dose-dependent fashion and, at the highest concentration tested (10.0 µM), EPA inhibited sdLDL oxidation by 94% contrast to vehicle treated (ethanol) control.
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States.
Dunkin Brands Group Inc (NASDAQ:DNKN)’s shares gained 0.53% to $54.60.
Dunkin Brands Group Inc (DNKN) declared the kick-off of a sweepstakes in partnership with Liverpool FC (LFC), one of the world’s most historic and famous football clubs. The sweepstakes will give fans in Vietnam the chance to score the ultimate LFC fan experience during the club’s forthcoming summer Southeast Asia tour and also celebrate Dunkin’ Donuts’ wide range of delicious coffees and baked goods.
From now through July 4th, Dunkin’ Donuts guests in Vietnam can earn an entry into the sweepstakes when they purchase a half dozen donuts. One lucky grand prize winner will receive a trip for two to Kuala Lumpur, Malaysia with three nights hotel accommodation, two tickets to the LFC match against Malaysia XI on July 24th in Kuala Lumpur, two tickets to an LFC training session and two tickets to an exclusive meet and greet with LFC players.
Dunkin Brands Group, Inc., together with its auxiliaries, develops, franchises, and licenses quick service restaurants under the Dunkin Donuts and Baskin-Robbins brands worldwide. The company operates through four segments: Dunkin’ Donuts U.S., Dunkin’ Donuts International, Baskin-Robbins U.S., and Baskin-Robbins International.
At the end of Thursday’s trade, Second Sight Medical Products Inc (NASDAQ:EYES)‘s shares dipped -4.39% to $15.04.
Second Sight Medical Products Inc (EYES) declared positive three year results post-implant of its Argus® II Retinal Prosthesis System (“Argus II”) from a multi-center clinical trial.
The paper titled, “Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind”, highlights 30 subjects implanted with the Argus II at 10 centers throughout the United States and Europe. Three types of visual function tests were performed using computer-run assessments: square localization (i.e. object detection), direction of motion (i.e. motion detection) and discrimination of oriented gratings (i.e. visual acuity). Two types of real-world orientation and mobility (O&M) tests were also performed: a test where subjects were asked to locate and touch a door, in addition to a test where subjects were asked to follow a white line on the floor. In the absence of existing validated quality of life tools for this population, a Functional Low-vision Observer Rated Assessment (FLORA) was also performed by independent visual rehabilitation experts at the request of the FDA to assess the impact of the Argus II system on the subjects’ everyday lives, counting extensive interviews and tasks performed around the home.
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the United States, Canada, Europe, and Saudi Arabia. It offers Argus II System, an implantable neurostimulation device that uses electrical stimulation of the retina to replace the function of the defunct photo-receptors in retinitis pigmentosa patients. Second Sight Medical Products, Inc. sells its Argus II System to university hospitals, teaching hospitals, medical centers, and ambulatory surgical centers.
StemCells Inc (NASDAQ:STEM), ended its Thursday’s trading session with 0.68% gain, and closed at $0.700.
StemCells Inc (STEM) a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, declared that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study(TM) is designed to assess the efficacy of the Company’s proprietary HuCNS-SC(R) platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury with the primary efficacy outcome being the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal cord.
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
